Who makes INV21 High Dose?

INV21 High Dose is developed by Inviragen Inc..

Last reviewed 2026-04-19 · How we verify

INV21 High Dose

Inviragen Inc. · Phase 1 active Biologic

At a glance

Generic name	INV21 High Dose
Also known as	INV21
Sponsor	Inviragen Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INV21 High Dose CI brief — competitive landscape report
INV21 High Dose updates RSS · CI watch RSS
Inviragen Inc. portfolio CI